|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Only among AA women, IL15 rs10833 and IL15RA rs2296135 were associated with ER-positive tumors, and IL12RB1 rs375947, IL15 rs10833 and TGFB1 rs1800469 were associated with ER-negative tumors.
|
23996684 |
2014 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
An HLA-dependent increase in CD137 expression was observed following incubation of fresh enzyme-digested tumor or ascites in IL-7 and IL-15 cytokines, but not IL-2.
|
24045181 |
2014 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Furthermore, Cox proportional hazard regression analysis revealed that tumor size (<i>p</i> = 0.012, <i>p</i> = 0.623), tumor thrombus (<i>p</i> = 0.011, <i>p</i> = 0.015), UCSF criteria (<i>p</i> = 0.471, <i>p</i> = 0.013), and recipient IL-15 rs10519613 genotype (<i>p</i> = 0.039, <i>p</i> = 0.008) were independent factors of predicting DFS and OS.
|
29162948 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we explored the different effects of IL-15 and IL-2 on tumor-infiltrating (TI) T cells from resected breast tumors.
|
26141233 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have demonstrated elevated expression levels of NF-kappa B--inducible cytokines, including interleukin (IL)-6, IL-10, IL-15, and interferon (IFN)-gamma, in freshly isolated primary tumors from Tax transgenic mice.
|
11493471 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Recombinant dsNKG2D-IL-15 thus inhibited NKG2D ligand-positive tumor growth effectively by activating lymphocytes.
|
24810637 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Both rNDV-IL15 and rNDV-IL2 effectively suppressed tumor growth compared with rNDV.
|
24645750 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We found that the intratumoral injection of Ad-CCL21-IL-15 into murine colon carcinomas significantly inhibited tumor growth.
|
24838092 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although IL-15 enhanced the trastuzumab mediated tumor defense, an unspecific immune stimulation resulted in preterm animal death due to systemic inflammation.
|
27835865 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our previous study have shown that CIK cells stimulated with combination of IL-2 and IL-15 displayed improved proliferation capacity and tumor cytotoxicity.
|
25108500 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Animals vaccinated with tumor cells coexpressing IL-15 and IL-15Rα showed greater tumor infiltration with CD8(+) T and natural killer (NK) cells, as well as increased antitumor CD8(+) T-cell responses.
|
24572789 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Treatment of tumor-bearing mice with DMA-pIL15 complex significantly inhibited tumor growth in both subcutaneous and peritoneal models <i>in vivo</i> by inhibiting angiogenesis, promoting apoptosis, and reducing proliferation through activation of the host immune system.
|
30026861 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity.
|
22565311 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In WSC, we identified an association between the plasmatic ANGPTL-4, IL-15, and IL-10 in tumor and IL-15 in MES.
|
31741709 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study has provided preclinical evidence that combined treatment with cytotoxic effector cells and CRAd-CCL20-IL15 may offer alternative treatment options for tumor therapy.
|
28651743 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We previously showed that bioactive IL15 <i>in vivo</i> comprises a stable complex of the IL15 chain with the IL15 receptor alpha chain (IL15Rα), termed heterodimeric IL15 (hetIL15).<b>Experimental Design:</b> We evaluated the effects of the combination regimen ACT + hetIL15 in the absence of lymphodepletion by transferring melanoma-specific Pmel-1 T cells into B16 melanoma-bearing mice.<b>Results:</b> hetIL15 treatment delayed tumor growth by promoting infiltration and persistence of both adoptively transferred Pmel-1 cells and endogenous CD8<sup>+</sup> T cells into the tumor.
|
27986749 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This suggests that IL-15 causes inflammation and changes in stroma that can promote decreased tumor cell proliferation.
|
28379958 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor morphology observation and growth indexes also showed that IL-15-transfected CIK cells had stronger cytotoxicity to tumor tissue than CIK cells.
|
26503216 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Juxtacrine function of interleukin-15/interleukin-15 receptor system in tumour derived human B-cell lines.
|
17100778 |
2006 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, we show that IL-15 transfection induced a selective expansion of antigen-specific CD4(+) T cells ex vivo and enhanced their tumor-suppression effects in vivo.
|
21822803 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We compared survival curves and tumor formation in IL-15 KO/MT, MT and IL-15 TG/MT groups.
|
25879689 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, the IL-15 culture prolonged the survival of animals bearing melanoma tumors after adoptive transfer.
|
23931270 |
2013 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, our data strongly indicated that tumor vaccine modified with NDV strain LX/IL(15+7) is a promising agent for cancer immunotherapy.
|
29224228 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
N592 cells engineered with IL-2 (N592/IL-2) were promptly rejected, while N592/IL-15 displayed a significant delay in tumour growth and a slightly reduced take rate.
|
10861581 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Expression of functional interleukin-15 receptor and autocrine production of interleukin-15 as mechanisms of tumor propagation in multiple myeloma.
|
10627470 |
2000 |